Arvinas, Inc. (ARVN) shares soared 8.8% in the last trading session to close at $9.03. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to Neutral. Analyst Price Forecast Suggests 554.89% Upside As of March 4 ...

In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the pump and dump stocks. Pump and dump stocks are typically characterized by high 52-week ...

Noah Berkowitz, the Chief Medical Officer of $ARVN, sold 8,658 shares of the company on 03-18-2025 for an estimated $74,372. We received data on the trade from a ...

Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54.9% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

ARVN stock opened at $17.50 on Thursday. The firm has a 50-day moving average price of $18.28 and a 200-day moving average price of $22.53. Arvinas has a 12 month low of $15.53 and a 12 month high ...

Arvinas (NASDAQ:ARVN – Free Report) had its price objective decreased by Bank of America from $54.00 to $28.00 in a research report report published on Wednesday morning,Benzinga reports.

Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research Report), Eledon Pharmaceuticals (ELDN – Research ...